These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 24921226)

  • 1. The pharmaco-economics of atypical antipsychotics.
    Taylor D; Aitchison K
    Int J Psychiatry Clin Pract; 1999; 3(4):237-48. PubMed ID: 24921226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of antipsychotic medication on psychiatric service utilization and cost.
    Rothbard A; Murrin MR; Jordan N; Kuno E; McFarland BH; Stroup TS; Morrissey JP; Stiles PG; Boothroyd RA; Merwin E; Shern DL
    J Ment Health Policy Econ; 2005 Jun; 8(2):83-93. PubMed ID: 15998980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotic safety and efficacy concerns.
    Meyer JM
    J Clin Psychiatry; 2007; 68 Suppl 14():20-6. PubMed ID: 18284274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Typical and atypical antipsychotics--the misleading dichotomy. Results from the Working Group 'Drugs in Psychiatry' (AGATE).
    Fischer-Barnicol D; Lanquillon S; Haen E; Zofel P; Koch HJ; Dose M; Klein HE;
    Neuropsychobiology; 2008; 57(1-2):80-7. PubMed ID: 18515977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In the aftermath of CATIE: how should administrators value atypical antipsychotic medications?
    Luchins DJ
    Adm Policy Ment Health; 2006 Sep; 33(5):541-3. PubMed ID: 16688482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmaco-economic evaluations of new drugs: potential key to a more efficient allocation of the health care budget].
    Delwel GO; Sprenger MJ
    Ned Tijdschr Geneeskd; 2002 Jun; 146(23):1068-71. PubMed ID: 12085554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States.
    Ascher-Svanum H; Furiak NM; Lawson AH; Klein TM; Smolen LJ; Conley RR; Culler SD
    J Med Econ; 2012; 15(3):531-47. PubMed ID: 22304338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Agreement between guidelines for pharmaco-economic research and never-before-published health-economics evaluations].
    Postma MJ; Kwik JJ; Rutten WJ; de Jong-van den Berg LT; Brouwers JR
    Ned Tijdschr Geneeskd; 2002 Jun; 146(23):1082-7. PubMed ID: 12085558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical antipsychotics and the burden of disease.
    Simpson GM
    Am J Manag Care; 2005 Sep; 11(8 Suppl):S235-41. PubMed ID: 16180961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia.
    Obradovic M; Mrhar A; Kos M
    Int J Clin Pract; 2007 Dec; 61(12):1979-88. PubMed ID: 17997804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are the second-generation antipsychotics cost-effective? A critical review on the background of different health systems.
    Hamann J; Leucht S; Kissling W
    Pharmacopsychiatry; 2003 Jan; 36(1):18-26. PubMed ID: 12649770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection of atypical antipsychotics for the management of schizophrenia.
    Sprague DA; Loewen PS; Raymond CB
    Ann Pharmacother; 2004 Feb; 38(2):313-9. PubMed ID: 14742771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipsychotic agents in the treatment of bipolar mania.
    Tohen M; Vieta E
    Bipolar Disord; 2009 Jun; 11 Suppl 2():45-54. PubMed ID: 19538685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Consumption and cost of antipsychotic drugs].
    Pérez J; Marín N; Vallano A; Castells X; Capellà D
    Actas Esp Psiquiatr; 2005; 33(2):110-6. PubMed ID: 15768318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of bipolar mania with atypical antipsychotics.
    Chengappa KN; Suppes T; Berk M
    Expert Rev Neurother; 2004 Nov; 4(6 Suppl 2):S17-25. PubMed ID: 16279862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recommended structure for reporting economic evaluation on pharmaceuticals in Belgium.
    Annemans L; Crott R; Degraeve D; Dubois D; Huybrechts M; Peys F; Robays H; Smets J; Tomas M; Vanschoubroek K;
    Pharm World Sci; 2002 Feb; 24(1):5-7. PubMed ID: 11980170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.